JPRN-UMIN000005127已完成1 期
Phase I study of peptide vaccination with CpG for patients with unresectable biliary tract cancer - Peptide vaccination with CpG for unresectable biliary tract cancer
Tokyo Women's Medical University0 个研究点目标入组 10 人开始时间: 2011年2月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Pregnancy or lactation 2.Decision of unsuitableness by principal investigator 3.Patient with severe underlying disease 4.Patient with severe allergy disease
研究者
相似试验
已完成
1 期
Phase I study of peptide-cocktail vaccination for HCV-positive patients with liver cancer who have undergone radical therapy.liver cancerJPRN-UMIN000003773Kurume University Cancer Vaccine Center3
已完成
1 期
Phase I study of peptide vaccination with GM-CSF for unresectable hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000004333Tokyo Women's Medical University9
进行中（未招募）
1 期
Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.Metastatic melanomaMedDRA version: 14.0Level: LLTClassification code 10025651Term: Malignant melanoma excisionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10042550Term: Superficial spreading melanoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10029488Term: Nodular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025662Term: Malignant melanoma of skin of scalp and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056768Term: Malignant melanoma of skin of lower limb, incl hipSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10048434Term: Melanoma malignant aggravatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10042548Term: Superficial spreading melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025652Term: Malignant melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018638-29-BECentre du Cancer des Cliniques Universitaires Saint-Luc6
进行中（未招募）
1 期
Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanomaEUCTR2010-020435-40-BECentre du Cancer3
已完成
1 期
Phase I clinical study of peptide vaccine using novel tumor-associated antigen TTK against advanced esophageal carcinomaAdvanced esophageal cancer refractory to standard therapeutic modalityJPRN-UMIN000001014niversity of Tokyo6